Xilio Therapeutics (XLO) Other Non Operating Income (2020 - 2026)

Xilio Therapeutics has disclosed Other Non Operating Income across 7 years of filings, most recently posting $1.3 million for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $1.3 million, up 118.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (down 31.97% YoY), and the FY2025 annual result was $1.1 million, down 52.97% from the prior year.
• Other Non Operating Income came in at $1.3 million for Q1 2026 at Xilio Therapeutics, up from $921000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $1.3 million in Q1 2026 to a low of -$1.4 million in Q2 2025.
• The 5-year median for Other Non Operating Income is $613000.0 (2023), against an average of $493000.0.
• Across the five-year window, Other Non Operating Income jumped 1347.54% in 2023 and plunged 283.31% in 2025, its largest moves.
• Xilio Therapeutics' Other Non Operating Income stood at $701000.0 in 2022, then slumped by 32.24% to $475000.0 in 2023, then climbed by 12.84% to $536000.0 in 2024, then jumped by 71.83% to $921000.0 in 2025, then jumped by 39.31% to $1.3 million in 2026.
• The last three Other Non Operating Income figures came in at $1.3 million (Q1 2026), $921000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.